Capitalizing on the Limitations of Current Therapies

Market Need

Meeting the Unmet, Global Medical Need to Combat Solid Tumor Recurrence and Metastasis

The growing demand for new cancer treatments can be attributed to a rapidly ageing population and changing environmental factors in western countries. The chances of developing cancer increase as a person gets older because more time has been available for mutations to accumulate.

According to the World Health Organization, all cancers (excluding non-melanoma skin cancer) are expected to increase from 8.2 million deaths, in 2012, to more than 10 million deaths by 2020, exceeding 13 million annual deaths by 2030.

36 million people die each year from non-communicable diseases like heart disease and stroke, diabetes, cancer and chronic lung disease (source).

Cancer is the leading cause of death worldwide, accounting for 9.6 million deaths in 2018 (source).

Providing a Competitive Advantage Over Other Treatments Available

Current drugs in the market offer, at most, a few months of extra life or tumor stabilization.

Our long-term therapy based on a pancreatic proenzyme formulation prevents tumor recurrence and metastasis, the main cause of patient death from cancer. Our lead product, PRP, has the potential to convert cancerous cells back to normal cell behavior.

How Our Technology Works What is PRP?

Sign up for email alerts

Be the first to receive breaking news

Sign up today